Stephen Lippard and Dario C. Altieri in conversation with Russel E. Kaufman and Thomas R. Tritton
On October 5, 2011, the Chemical Heritage Foundation and The Wistar Institute presented Cancer Therapies: 19th Century to Tomorrow, featuring Dario C. Altieri and Stephen J. Lippard in conversation with Russel E. Kaufman and Thomas R. Tritton.
Evolving cancer therapies were discussed, from the travails of 19th-century medicine, to the increasing success of 20th-century care, to the promising research under way today that gives hope for the future.
Dario C. Altieri
Dario C. Altieri is the director of The Wistar Institute Cancer Center and chief scientific officer at The Wistar Institute. Altieri was formerly a professor at the Yale University School of Medicine and founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School. In 2005 he cofounded both the National Cancer Biology
Training Consortium, which promotes scientific excellence in the next generation of cancer researchers, and the Pancreatic Cancer Alliance, an all-volunteer patient advocacy organization devoted to supporting pancreatic cancer research and education.
Altieri began his current position at The Wistar Institute in 2010. His work explores the mechanisms that underlie how tumor cells survive and proliferate in cancer. In particular, members of his laboratory investigate how tumor cells evade the normal processes that cause cells with genetic faults to self-destruct. Understanding these mechanisms could provide new therapeutic targets and novel approaches for virtually every type of human cancer. To date, Altieri’s research has resulted in 9 patents and over 170 scientific articles.
Altieri earned a Ph.D. and postgraduate specialty degree in clinical and experimental hematology at the University of Milan School of Medicine.
Stephen J. Lippard
Stephen J. Lippard is the Arthur Amos Noyes Professor of Chemistry at the Massachusetts Institute of Technology.
Lippard’s research activities span the fields of inorganic chemistry, biological chemistry, and neurochemistry. His work includes studies to understand and improve platinum anticancer drugs, the synthesis of diiron complexes as models for carboxylate-bridged diiron metalloenzymes, and investigations of inorganic neurotransmitters and signal transducers, especially nitric oxide and zinc.
The chemistry investigated in Lippard’s laboratory explores the interface between inorganic chemistry and biology. Core activities include structural and mechanistic studies of macromolecules as well as synthetic inorganic chemistry. The focus is on the synthesis, reactions, and physical and structural properties of metal complexes as models for the active sites of metalloproteins and as anticancer drugs. Also included is extensive structural and mechanistic work on the natural systems themselves. A program in metalloneurochemistry devises small molecule probes of inorganic ions and molecules that are involved in cell signaling and applies them to study neurotransmission.
Lippard received a bachelor’s degree in chemistry from Haverford College and a Ph.D. in inorganic chemistry from the Massachusetts Institute of Technology.
Russel E. Kaufman is president and CEO of The Wistar Institute.
Thomas R. Tritton is president and CEO of CHF.